A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Phase 3
Completed
NCT06238817
| Condition | Atopic Dermatitis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Incyte Corporation |
|---|
| Status | Completed |
|---|
| Enrollment | 241 participants |
|---|
| Interventions | Ruxolitinib Cream, Vehicle Cream |
|---|
| Start date | Apr 26, 2024 |
|---|
| Completion date | May 21, 2025 |
|---|
| Results posted | May 22, 2026 |
|---|
Summary
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 18.5 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 70.0 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 11.26 (95% CI 5.692–22.260) |
|---|
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 13.6 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 61.3 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 10.14 (95% CI 4.904–20.975) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.